Kinarus Therapeutics Holding AG
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
KNRS | SW
Overview
Corporate Details
- ISIN(s):
- CH1330780979
- LEI:
- 506700VDL70GGMHR5758
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Website:
- https://www.curatis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Following a 2024 reverse takeover, Kinarus Therapeutics Holding AG was renamed and now operates as Curatis Holding AG, a specialty pharmaceutical company. The firm focuses on acquiring, developing, and commercializing innovative medicines for rare and specialty care diseases. It operates two business segments: a distribution arm that licenses and commercializes over 40 third-party specialty medicines, primarily in Switzerland, and a development arm focused on advancing a pipeline of novel drugs. The development strategy prioritizes compounds with existing safety and efficacy data to lower risk. Key pipeline candidates target pediatric peritumoral brain edema (C-PTBE-01), severe migraine (C-AM-01), medication overuse headache (C-MOH-01), and rare inflammatory diseases (KIN001).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-18 07:00 |
Regulatory News Service
FDA minutes confirm positive outcome of meeting on 9. September 2025 Corticore…
|
English | 9.4 KB | ||
| 2025-09-18 02:00 |
Regulatory News Service
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticor…
|
English | 11.0 KB | ||
| 2025-09-18 00:00 |
Investor Presentation
Investor Presentation
|
English | 1.1 MB | ||
| 2025-09-15 07:00 |
Earnings Release
Curatis: Double-digit growth in core business and
development milestone achieve…
|
English | 19.7 KB | ||
| 2025-09-15 02:00 |
Earnings Release
Curatis: Double-digit growth in core business and
development milestone achieve…
|
English | 22.5 KB | ||
| 2025-09-05 07:00 |
Regulatory News Service
Curatis expands distribution business with Phoenix Labs with up to CHF 5m addit…
|
English | 6.3 KB | ||
| 2025-09-05 02:00 |
Regulatory News Service
Curatis expands distribution business with Phoenix Labs with up to CHF 5m addit…
|
English | 7.8 KB | ||
| 2025-07-31 06:00 |
Legal Proceedings Report
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
|
English | 8.0 KB | ||
| 2025-07-31 02:00 |
Legal Proceedings Report
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
|
English | 9.7 KB | ||
| 2025-05-25 11:31 |
Post-Annual General Meeting Information
Annual General Meeting of Curatis Holding AG approved all proposals of the Boar…
|
English | 7.1 KB | ||
| 2025-05-24 02:00 |
Post-Annual General Meeting Information
Annual General Meeting of Curatis Holding AG approved all proposals of the Boar…
|
English | 8.8 KB | ||
| 2025-05-23 07:00 |
Regulatory News Service
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opport…
|
English | 13.1 KB | ||
| 2025-05-23 02:00 |
Regulatory News Service
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opport…
|
English | 15.4 KB | ||
| 2025-05-23 00:00 |
Investor Presentation
Investor Presentation
|
English | 958.3 KB | ||
| 2025-05-02 00:00 |
Registration Form
Articles of Incorporation
|
German | 2.0 MB |
Automate Your Workflow. Get a real-time feed of all Kinarus Therapeutics Holding AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Kinarus Therapeutics Holding AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-02 | N/A | Non-Executive member | Buy | None | 337,068.73 CHF |
| 2022-06-02 | N/A | Executive member | Buy | None | 126,706.95 CHF |
| 2022-06-02 | N/A | Non-Executive member | Buy | None | 104,185.81 CHF |
